Hayashi Yoshiki, Kuriyama Hideyuki, Umezu Hajime, Tanaka Junta, Yoshimasu Tatsuya, Furukawa Tomoko, Tanaka Hiroshi, Kagamu Hiroshi, Gejyo Fumitake, Yoshizawa Hirohisa
Division of Respiratory Medicine, Niigata University Graduate School of Medical and Dental Sciences, Japan.
Intern Med. 2009;48(4):203-8. doi: 10.2169/internalmedicine.48.1659. Epub 2009 Feb 16.
To assess the relationship between in vitro chemosensitivity evaluated by the histoculture drug response assay (HDRA) and the expression of beta-tubulin isotypes in tumors of patients with completely resected NSCLC in order to determine the predictive value of beta-tubulin in chemotherapy for NSCLC.
Expression of beta-tubulin isotypes was immunohistochemically analyzed in a series of 58 tumor samples from patients with completely resected NSCLC. The sensitivity of individual tumors to anticancer agents was evaluated by HDRA.
Class III beta-tubulin expression by tumor cells was significantly correlated with resistance to docetaxel (p=0.0250), but not related with resistance to gemcitabine. Patient characteristics (age, gender, histology, and stage) were not associated with class III beta-tubulin expression.
An abundance of class III beta-tubulin in tumor cells could be a biomarker for resistance to docetaxel in patients with completely resected NSCLC.
通过组织培养药物反应试验（HDRA）评估体外化学敏感性与完全切除的非小细胞肺癌（NSCLC）患者肿瘤中β-微管蛋白异构体表达之间的关系，以确定β-微管蛋白在NSCLC化疗中的预测价值。
对一系列来自完全切除NSCLC患者的58个肿瘤样本进行免疫组织化学分析，检测β-微管蛋白异构体的表达。通过HDRA评估各个肿瘤对抗癌药物的敏感性。
肿瘤细胞中III类β-微管蛋白的表达与对多西他赛的耐药性显著相关（p = 0.0250），但与对吉西他滨的耐药性无关。患者特征（年龄、性别、组织学类型和分期）与III类β-微管蛋白表达无关。
肿瘤细胞中大量的III类β-微管蛋白可能是完全切除的NSCLC患者对多西他赛耐药的生物标志物。
